Brain Dopamine Function in Human Obesity

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

March 31, 2022

Study Completion Date

February 17, 2023

Conditions
ObesityHealthy VolunteersOverweight
Interventions
DRUG

[c11] raclopride

The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.

DRUG

[18F]fallypride

The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT03648892 - Brain Dopamine Function in Human Obesity | Biotech Hunter | Biotech Hunter